Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAPNS1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CAPNS1 siRNA is a research-stage small interfering RNA (siRNA) compound designed to silence the *CAPNS1* gene, which encodes Calpain Small Subunit 1 (also known as CPNS1). CPNS1 is the regulatory small subunit shared by calpain-1 and calpain-2, which are calcium-dependent cysteine proteases involved in various cellular processes including apoptosis, cell migration, and protein degradation. In preclinical research, CAPNS1 siRNA is used as a molecular biology tool to knock down CAPNS1 expression in cancer cell lines, such as gastric and prostate cancer models, to study its role in chemotherapy resistance and genome integrity. While patents (e.g., WO2009090639) describe its potential therapeutic application in neurodegenerative and oncological disorders, it is currently primarily available as a research-use-only reagent from various suppliers and has not entered formal clinical development under a specific sponsor.
- Other names
- Calpain small subunit 1 siRNACPNS1 siRNACPNS-1 siRNACPNS 1 siRNAsiRNA targeting CAPNS1
02
Targets
CAPN (Schistosoma calpain large subunit family)
Beyond the preview
Go deeper on CAPNS1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAPNS1 siRNA.